Novel class of LPPOs could provide alternative to antibiotics, study shows
Lipophosphonoxins may represent the next generation of antibiotics and can be delivered using a new type of dressing for skin wounds.
List view / Grid view
Lipophosphonoxins may represent the next generation of antibiotics and can be delivered using a new type of dressing for skin wounds.
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.
The new CRISPR-based technology called MIC-Drop rapidly identified several genes for heart development and function in zebrafish.
A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
Artificial intelligence was shown to predict the 3D shapes of RNA molecules, which could significantly advance RNA therapeutics.
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
An artificial intelligence technique can identify which neoantigens are recognised by the immune system, possibly improving cancer prognosis and treatment.
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
The over-expression of a growth factor receptor resulted in hypomyelination, leading to diseases such as multiple sclerosis in mouse models.
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.